Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)
This study is currently recruiting participants.
Verified July 2010 by Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Study NCT01081431
Information provided by Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
First Received on March 2, 2010.
Last Updated on June 24, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
